Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07064460 · ClinicalTrials.gov registry record · NA
Duke Customized Aortic Aneurysm Repair With Endovascular Stent-grafts - Duke CARES Trial
A NA study of Aortic Disorders, sponsored by Chandler Long, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07064460: Recruiting NA study of Aortic Disorders, sponsored by Chandler Long, MD.
NCT07064460 is a NA study of Aortic Disorders that is actively recruiting participants, run by Chandler Long, MD. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07064460, a NA study of Aortic Disorders, is actively recruiting participants, sponsored by Chandler Long, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if physician modified endovascular grafts (PMEG) can be used safely for the treatment of aortic disorders. The surgeon will modify a commercially available graft tailored to the participant's anatomy for surgery. The researchers will follow participants for 5 years, which will require regular visits to the clinic for follow-up imaging and follow-up blood tests.
Primary Outcome
The primary safety endpoint is freedom from major adverse events (MAE) at 30 days or during hospitalization if this exceeds 30 days. MAE include death, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, and estimated procedural blood loss \> 1000 cc.
Conditions Studied
Interventions
- DEVICE Physician Modified Endovascular Graft
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01-13 |
| Est. Completion | 2031-12-11 |
| Phase | NA |
What NCT07064460 shows while recruiting
NCT07064460 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Aortic Disorders appearing as the primary indexed condition, and to 1 intervention - of which Physician Modified Endovascular Graft is the first listed.
NCT07064460 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT07064460 about?
NCT07064460 is a clinical study titled "Duke Customized Aortic Aneurysm Repair With Endovascular Stent-grafts - Duke CARES Trial". The purpose of this study is to see if physician modified endovascular grafts (PMEG) can be used safely for the treatment of aortic disorders. The surgeon will modify a commercially available graft tailored to the participant's anatomy for surgery. The researchers will follow participants for 5 year...
What is the current status of trial NCT07064460?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-01-13. Estimated completion is 2031-12-11.
What conditions does trial NCT07064460 study?
This clinical trial studies the following conditions: Aortic Disorders.
What interventions are being tested in trial NCT07064460?
The interventions under investigation include: Physician Modified Endovascular Graft (DEVICE).
Who is sponsoring clinical trial NCT07064460?
This trial is sponsored by Chandler Long, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07064460 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07064460's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI